Evidence map›Paper›PMID 32389360›Full record

ReviewGastroenterology clinics of North America2020

Hepatitis B: Current Status of Therapy and Future Therapies.

Elias Spyrou, Coleman I Smith, Marc G Ghany

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Gastroenterology clinics of North America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. [A clinically cured case of chronic hepatitis B].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024
    Article
  4. Article
  5. Article
  6. Prevention in Hepatology.Journal of personalized medicine · 2024
    Review
  7. New Treatment Options in Chronic Hepatitis B: How Close Are We to Cure?Infectious diseases & clinical microbiology · 2023
    Review
  8. Observational
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Elias SpyrouMedStar Georgetown Transplant Institute, MedStar Georgetown University Hospital, Washington, DC, USA; Nazih Zuhdi Transplant Institute, INTEGRIS Baptist Medical Center, Oklahoma City, OK, USA.
Coleman I SmithMedStar Georgetown Transplant Institute, MedStar Georgetown University Hospital, Washington, DC, USA.
Marc G GhanyLiver Diseases Branch, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Building 10, Room 9B-16, 10 Center Drive MSC 1800, Bethesda, MD 20892-1800, USA. Electronic address: marcg@intra.niddk.nih.gov.
Georgetown University · USMedStar Georgetown University Hospital · USNational Institutes of Health · US

Funding

Natural History, Therapy and Pathogenesis of Chronic Viral Hepatitis BZ01DK054517 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI GHANY, MARC · 2008 to 2008
$567k
Intramural NIH HHS Z01 DK054517
6 · The paper itself

Abstract

Despite the availability of a protective vaccine for over 3 decades, the number of persons with chronic hepatitis B virus (HBV) infection remains high. These persons are at risk for cirrhosis and hepatocellular carcinoma. Current treatment is effective at inhibiting viral replication and reducing complications of chronic HBV infection, but is not curative. There is a need for novel, finite therapy that can cure chronic HBV infection. Several agents are in early-phase development and can be broadly viewed as agents that target the virus directly or indirectly or the host immune response. This article highlights key developments in antiviral/immunomodulatory therapy, the rationale for these approaches, and possible therapeutic regimens.

Indexed as

ImmunomodulationAntiviral AgentsCarcinoma, HepatocellularFemaleHepatitis BHepatitis B virusHumansLiver CirrhosisLiver NeoplasmsMalePrevalenceAntiviral AgentsAntiviral/immunomodulatory therapyCirrhosisHepatocellular carcinomaInfectionVaccines

Identifiers

PMID32389360
PMCPMC7444867
OpenAlexW3013475142

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.